Published in Pharmacol Biochem Behav on June 01, 1987
Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther (2011) 2.75
Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology (2007) 2.55
Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine. Eur J Pharmacol (1976) 2.14
Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. Br J Surg (2015) 2.11
Sensitivity of ribonucleic acid and deoxyribonucleic acid viruses to different species of interferon in cell cultures. J Virol (1972) 2.09
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A (1990) 1.82
Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies. J Clin Invest (1976) 1.78
5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology (1986) 1.78
Chronic developmental lead exposure reduces neurogenesis in adult rat hippocampus but does not impair spatial learning. Toxicol Sci (2005) 1.77
Functional consequences of posttranslational isomerization of Ser46 in a calcium channel toxin. Science (1994) 1.73
Actions of dopaminergic agonists on motor function. Adv Neurol (1975) 1.72
Sequence determination of the capsid protein gene and flanking regions of tobacco etch virus: Evidence for synthesis and processing of a polyprotein in potyvirus genome expression. Proc Natl Acad Sci U S A (1985) 1.70
Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther (2007) 1.70
Cyst decompression surgery for autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1992) 1.68
Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav (1989) 1.64
Nomifensine: a potent dopaminergic agonist of antiparkinson potential. Psychopharmacologia (1975) 1.63
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer (2003) 1.48
5-Hydroxytryptamine receptor antagonism by metoclopramide and ICS 205-930 in the guinea-pig leads to enhancement of contractions of stomach muscle strips induced by electrical field stimulation and facilitation of gastric emptying in-vivo. J Pharm Pharmacol (1985) 1.46
Cumulative radiation dose during hospitalization for aneurysmal subarachnoid hemorrhage. AJNR Am J Neuroradiol (2010) 1.42
Medical students' views on selection tools for medical school--a mixed methods study. Ir Med J (2014) 1.41
Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphe nuclei. Eur J Pharmacol (1974) 1.36
Thyroid hormones, brain function and cognition: a brief review. Neurosci Biobehav Rev (2002) 1.36
Biochemical changes during development of mouse mammary tissue in organ culture. J Endocrinol (1970) 1.31
Effect of cations on the consideration of hen erythrocyte nuclei and its relation to gene activation. Exp Cell Res (1972) 1.29
Atropine occlusion in the treatment of strabismic amblyopia and its effect upon the non-amblyopic eye. Ophthalmic Physiol Opt (1991) 1.28
Curative cerebrovascular reconstruction with the Pipeline embolization device: the emergence of definitive endovascular therapy for intracranial aneurysms. J Neurointerv Surg (2009) 1.28
Stimulation by insulin of the formation of ribonucleic acid and protein by mammary tissues in vitro. Biochem J (1966) 1.26
Increase in activity of glucose 6-phosphate dehydrogenase in mouse mammary tissue cultured in insulin. Biochem J (1969) 1.24
Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int (1996) 1.22
Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung (1973) 1.20
Stereotypic and anticataleptic activities of amphetamine after intracerebral injections. Eur J Pharmacol (1972) 1.19
Post-weaning housing conditions influence the behavioural effects of cocaine and d-amphetamine. Psychopharmacology (Berl) (1997) 1.19
Neuropharmacology of emesis in relation to clinical response. Br J Cancer Suppl (1992) 1.18
Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology (1975) 1.17
Gestational stress induces post-partum depression-like behaviour and alters maternal care in rats. Psychoneuroendocrinology (2004) 1.17
Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev (1987) 1.17
Role of histones in chromatin condensation. Eur J Biochem (1974) 1.17
Mitogen-activated protein and tyrosine kinases in the activation of astrocyte volume-activated chloride current. J Neurosci (1998) 1.16
Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride. J Pharm Pharmacol (1988) 1.16
Neuroleptic antagonism of dyskinetic phenomena. Eur J Pharmacol (1976) 1.16
Needle tract seeding after percutaneous renal adenocarcinoma aspiration. J Urol (1986) 1.15
Increase during lactation of RNA synthesis b isolated liver nuclei. Biochim Biophys Acta (1968) 1.15
5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol (1990) 1.14
The 6-hydroxydopamine rotational model for the detection of dopamine agonist activity: reliability of effect from different locations of 6-hydroxydopamine. J Pharm Pharmacol (1975) 1.13
The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav (1989) 1.13
Swelling of hen erythrocyte nuclei in cytoplasm from Xenopus eggs. Exp Cell Res (1972) 1.12
Kindling modulates the IL-1beta system, TNF-alpha, TGF-beta1, and neuropeptide mRNAs in specific brain regions. Brain Res Mol Brain Res (2000) 1.12
A role for the amygdala in the development of the cataleptic and stereotypic actions of the narcotic agonists and antagonists in the rat. Psychopharmacologia (1974) 1.11
The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist. Br J Pharmacol (1988) 1.11
Circling behaviour produced by asymmetric medial raphé nuclei lesions in rats. J Pharm Pharmacol (1976) 1.10
gamma-Aminobutyric acid(A) receptor subunit expression predicts functional changes in hippocampal dentate granule cells during postnatal development. J Neurochem (2001) 1.10
The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur J Pharmacol (1975) 1.08
5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature (1989) 1.08
Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res (1989) 1.08
Renal function 27 years after unilateral nephrectomy for related donor kidney transplantation. J Urol (1988) 1.08
Zacopride, a potent 5-HT3 antagonist. J Pharm Pharmacol (1988) 1.07
The psychopharmacology of 5-HT3 receptors. Pharmacol Ther (1990) 1.06
Clinical experience with hinged silicone penile implants for impotence. J Urol (1980) 1.06
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav (1991) 1.05
Cyst fluid antibiotic concentrations in autosomal-dominant polycystic kidney disease. Am J Kidney Dis (1985) 1.04
Role of splenectomy in renal transplantation. Urology (1973) 1.04
5-HT4 receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea-pig isolated ileum. Br J Pharmacol (1993) 1.03
Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain. Neuropharmacology (1972) 1.02
Evidence for a 5-HT3 receptor involvement in the facilitation of peristalsis on mucosal application of 5-HT in the guinea pig isolated ileum. Br J Pharmacol (1997) 1.01
Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology (1990) 1.01
Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol (1987) 1.01
Serotoninergic modulation of the dopamine response from the nucleus accumbens. J Pharm Pharmacol (1976) 1.00
The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol (1987) 1.00
Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect? Psychopharmacologia (1973) 1.00
Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int (1983) 0.99